What The Study Did: Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Authors: Richard B. Lipton, M.D., of the Albert Einstein College of Medicine in Bronx, New York, is the corresponding author.
(doi:10.1001/jama.2019.16711)
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.